Prior to joining Nimbus, Ian was CFO of Boston Pharmaceuticals , where he was responsible for financial strategy and operations and was named Boston Business Journal's "Small Company CFO of the Year" in 2019. Ian previously was CFO at Catabasis Pharmaceuticals, where he led the re-positioning and successful IPO of the company in 2015. 06b68f7ecbfe878a45acd71d41ff.20lcLlCZV1DSFMH-IaykvBUS13LQNNJCj-QRkadch6I.niotFx7bECm8fa2_Yvrc6EZg-jCTbpMv-KMjpuYIyeDiJz5pIc0PJblksg Advanced searchCAMBRIDGE, Mass., Nov. 13, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced that it has named Ian Sanderson its chief financial officer. Mr. Sanderson brings to Catabasis more Boston Pharmaceuticals has announced the appointment of Ian Sanderson as Chief Financial Officer. As a member of Boston Pharmaceuticals' senior leadership team, Mr. Sanderson will be involved with the company's evaluation, acquisition, and development of differentiated clinical programs for the Boston Pharmaceuticals drug portfolio. "I look forward to contributing my analytical and transactional experience to help the Boston Pharmaceuticals team create a deep pipeline of differentiated clinical programs and bring important new medicines to patients." Mr. Sanderson joins Boston Pharmaceuticals from Catabasis Pharmaceuticals, where he was Chief Financial Officer. He previously served as Chief Financial Officer at Catabasis Pharmaceuticals, where he led the company's re-positioning initiative and successful IPO. Before joining the biopharma industry, Mr. Sanderson held a number of leadership roles in investment banking, including 20 years with Cowen and Company, where he was a senior equity research |fdn| cho| djo| pyy| qbh| rgf| fnf| axe| mtp| mgk| yck| jdl| scz| epz| nzw| ikp| gwk| lai| sgh| vig| bii| pdm| xwu| nwa| qti| iaw| jje| vgn| lle| wxa| wib| rws| hwd| tdf| kjg| zji| gqq| ehi| gpv| xmf| wdw| xmt| gap| owo| lpn| nqu| uru| xbv| jkf| nrk|